Beijing Luzhu Biotechnology (HKG:2480) biologics license application for LZ901 was accepted by China's National Medical Products Administration, a Feb. 9 Hong Kong bourse filing said.
LZ901 is a recombinant herpes zoster vaccine candidate aimed at preventing the occurrence of herpes zoster and related complications, according to the drugmaker.